COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00227773
Recruitment Status : Withdrawn
First Posted : September 28, 2005
Last Update Posted : October 8, 2015
National Cancer Institute (NCI)
Information provided by:
Eastern Cooperative Oncology Group

Tracking Information
First Submitted Date  ICMJE September 26, 2005
First Posted Date  ICMJE September 28, 2005
Last Update Posted Date October 8, 2015
Study Start Date  ICMJE Not Provided
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE Not Provided
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Official Title  ICMJE Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors
Brief Summary

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide may be an effective treatment for neuroendocrine tumors.

PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide works in treating patients with progressive neuroendocrine tumors.

Detailed Description


  • Determine the 4-month progression-free and overall survival of patients with progressive low-grade neuroendocrine tumors treated with vatalanib and octreotide.
  • Determine the response rate in patients treated with this regimen.
  • Determine the effect of this regimen on tumor markers (e.g., chromogranin A, 5-HIAA, and gastrin) in these patients.
  • Determine the toxicity and tolerability of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral vatalanib once daily on days 1- 28 and octreotide* intramuscularly or IV on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients on a stable dose (i.e., no changes in dosage within the past 3 months) of octreotide before study entry remain on their current dose and schedule during study participation; patients who experience hypersensitivity and/or toxicity to octreotide may receive vatalanib alone.

After completion of study treatment, patients are followed at 4 weeks, every 3 months for 2 years, and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 3 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE
  • Gastrointestinal Carcinoid Tumor
  • Islet Cell Carcinoma
Intervention  ICMJE
  • Drug: octreotide acetate
  • Drug: vatalanib
  • Procedure: anti-cytokine therapy
  • Procedure: antiangiogenesis therapy
  • Procedure: biological therapy
  • Procedure: endocrine therapy
  • Procedure: enzyme inhibitor therapy
  • Procedure: growth factor antagonist therapy
  • Procedure: hormone therapy
  • Procedure: protein tyrosine kinase inhibitor therapy
  • Procedure: somatostatin analogue therapy
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: October¬†6,¬†2015)
Original Enrollment  ICMJE Not Provided
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE


  • Histologically confirmed low-grade neuroendocrine tumors
  • The following tumor types are excluded:
  • Small cell lung cancer
  • Medullary thyroid cancer
  • Paraganglioma
  • Pheochromocytoma
  • Measurable disease
  • Radiographic evidence of disease progression after completion of any prior systemic therapy, chemoembolization, bland embolization, or observation within the past year, defined as either of the following:
  • Appearance of a new lesion
  • At least 20% increase in the longest diameter (LD) of any previously documented lesion or an increase in the sum of the LDs of multiple lesions in the aggregate of 20%



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Absolute neutrophil count ≥ 1,000/mm^3
  • Platelet count ≥ 75,000/mm^3
  • Hemoglobin ≥ 8.0 g/dL


  • Bilirubin ≤ 2.0 times upper limit of normal (ULN)
  • AST ≤ 3 times ULN (5 times ULN if liver metastases are present)


  • Creatinine ≤ 1.5 times ULN
  • Meets 1 of the following criteria:
  • Urine protein negative by dipstick
  • Urine protein:creatinine ratio < 1.0
  • Urine protein < 1 g by 24-hour urine collection


  • Must be able to swallow tablets
  • No ulcerative disease
  • No uncontrolled nausea, vomiting, or diarrhea
  • No bowel obstruction
  • No other gastrointestinal tract disease resulting in an inability to take oral medication


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Must be able to receive a contrast-enhanced CT scan
  • No known history of allergic reaction to vatalanib or its derivatives or octreotide injections


Biologic therapy

  • Not specified


  • At least 4 weeks since prior chemotherapy
  • No more than 1 prior systemic chemotherapy regimen
  • Chemoembolization is not considered systemic chemotherapy
  • No concurrent chemotherapy

Endocrine therapy

  • Not specified


  • At least 3 weeks since prior radiotherapy
  • No concurrent radiotherapy


  • At least 4 weeks since prior major surgery


  • At least 4 weeks since other prior systemic therapy
  • At least 4 weeks since prior local liver therapy
  • No prior anti-vascular endothelial growth factor agents
  • No concurrent grapefruit or grapefruit juice
  • No concurrent therapeutic warfarin or similar oral anticoagulants that are metabolized by the cytochrome P450 system
  • Concurrent heparin allowed
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 120 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00227773
Other Study ID Numbers  ICMJE CDR0000446076
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Eastern Cooperative Oncology Group
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Study Chair: Kyle Holen, MD University of Wisconsin, Madison
Investigator: Mary Mulcahy, MD Robert H. Lurie Cancer Center
PRS Account Eastern Cooperative Oncology Group
Verification Date October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP